Challenges and Pitfalls of Using Repeat Spirometry Recordings in Routine Primary Care Data to Measure FEV
COPD
electronic healthcare records
lung function
spirometry
Journal
Pragmatic and observational research
ISSN: 1179-7266
Titre abrégé: Pragmat Obs Res
Pays: New Zealand
ID NLM: 101688693
Informations de publication
Date de publication:
2021
2021
Historique:
received:
12
05
2021
accepted:
06
07
2021
entrez:
13
9
2021
pubmed:
14
9
2021
medline:
14
9
2021
Statut:
epublish
Résumé
Electronic healthcare records (EHR) are increasingly used in epidemiological studies but are often viewed as lacking quality compared to randomised control trials and prospective cohorts. Studies of patients with chronic obstructive pulmonary disease (COPD) often use the rate of forced expiratory volume in 1 second (FEV Clinical Practice Research Datalink and Hospital Episode Statistics were used. Patient populations were defined using 8 sets of criteria around repeated FEV For 7/8 patient populations, rates of FEV FEV
Sections du résumé
BACKGROUND
BACKGROUND
Electronic healthcare records (EHR) are increasingly used in epidemiological studies but are often viewed as lacking quality compared to randomised control trials and prospective cohorts. Studies of patients with chronic obstructive pulmonary disease (COPD) often use the rate of forced expiratory volume in 1 second (FEV
METHODS
METHODS
Clinical Practice Research Datalink and Hospital Episode Statistics were used. Patient populations were defined using 8 sets of criteria around repeated FEV
RESULTS
RESULTS
For 7/8 patient populations, rates of FEV
CONCLUSION
CONCLUSIONS
FEV
Identifiants
pubmed: 34512071
doi: 10.2147/POR.S319965
pii: 319965
pmc: PMC8420778
doi:
Types de publication
Journal Article
Langues
eng
Pagination
119-130Informations de copyright
© 2021 Whittaker et al.
Déclaration de conflit d'intérêts
HW reports grants from GSK, AZ, and BI, outside the submitted work; SK reports grants from Medical Research Council, during the conduct of the study; personal fees from Roche Diagnostics, personal fees from DIADEM, personal fees from AstraZeneca, outside the submitted work; JQ reports grants from British Lung Foundation and personal fees from AZ, Asthma UK, BI, Bayer, GSK, MRC, and Chiesi, outside the submitted work. The authors report no other conflicts of interest in this work.
Références
N Engl J Med. 2011 Sep 29;365(13):1184-92
pubmed: 21991892
BMJ Open. 2014 Jul 23;4(7):e005540
pubmed: 25056980
Int J Chron Obstruct Pulmon Dis. 2015 Sep 07;10:1819-27
pubmed: 26379432
Int J Epidemiol. 2015 Jun;44(3):827-36
pubmed: 26050254
Thorax. 2002 Oct;57(10):847-52
pubmed: 12324669
N Engl J Med. 2014 Oct 2;371(14):1285-94
pubmed: 25196117
Eur Respir J. 2006 Dec;28(6):1245-57
pubmed: 17138679
Eur Respir J. 2008 Apr;31(4):742-50
pubmed: 18256071
Thorax. 2020 Sep;75(9):714-715
pubmed: 32580992
Respir Res. 2014 Aug 31;15:102
pubmed: 25175805
Eur Respir J. 1993 Mar;6 Suppl 16:5-40
pubmed: 24576915
Int J Chron Obstruct Pulmon Dis. 2012;7:95-9
pubmed: 22371650
Int J Chron Obstruct Pulmon Dis. 2017 Jun 07;12:1663-1668
pubmed: 28652719
Eur Respir J. 2021 Mar 4;57(3):
pubmed: 32972984
Am J Respir Crit Care Med. 2018 Jan 1;197(1):47-55
pubmed: 28737971
Respir Res. 2019 Dec 4;20(1):277
pubmed: 31801539
Int J Chron Obstruct Pulmon Dis. 2019 May 23;14:1063-1073
pubmed: 31213788
Int J Chron Obstruct Pulmon Dis. 2020 Nov 25;15:3079-3091
pubmed: 33268984
Respir Res. 2018 Dec 13;19(1):251
pubmed: 30545350
Thorax. 2006 Jun;61(6):472-7
pubmed: 16517577
Eur Respir J. 2019 Mar 14;53(3):
pubmed: 30578401